Page 1 | Search Results | Cancer Immunology Research | American Association for Cancer Research

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Antitumor CD4⁺ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells

Ganesan Ramamoorthi, Marie Catherine Lee, Carly M. Farrell, Colin Snyder, Saurabh K. Garg, Amy L. Aldrich, Vincent Lok, William Dominguez-Viqueira, Sy K. Olson-Mcpeek, Marilin Rosa, Namrata Gautam, Shari Pilon-Thomas, Ling Cen, Krithika N. Kodumudi, Doris Wiener, Thordur Oskarsson, Ana P. Gomes, Robert A. Gatenby, Brian J. Czerniecki

Cancer Immunol Res OF1–OF20.

https://doi.org/10.1158/2326-6066.CIR-24-0630

Published: 18 April 2025

View articletitled, Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells

Includes: Supplementary data

Journal Articles

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4⁺ Th1 Responses and Potential Use as a Cancer Vaccine

Amrita Basu, Gabriella K. Albert, Sabrina Awshah, Jashodeep Datta, Krithika N. Kodumudi, Corey Gallen, Amber Beyer, Keiran S.M. Smalley, Paulo C. Rodriguez, Derek R. Duckett, Peter A. Forsyth, Aixa Soyano, Gary K. Koski, Ricardo Lima Barros Costa, Heather Han, Hatem Soliman, Marie Catherine Lee, Pawel Kalinski, Brian J. Czerniecki

Cancer Immunol Res (2022) 10 (1): 108–125.

https://doi.org/10.1158/2326-6066.CIR-21-0454

Published: 01 January 2022

View articletitled, Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine

Includes: Supplementary data

Journal Articles

Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity

Cancer Immunol Res (2021) 9 (5): 554–567.

https://doi.org/10.1158/2326-6066.CIR-20-0905

Published: 01 May 2021

View articletitled, Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity

Includes: Supplementary data

Journal Articles

CD4⁺ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8⁺ T-cell Targeting of HER2/neu–Expressing Cancers

Jashodeep Datta, Shuwen Xu, Cinthia Rosemblit, Jenessa B. Smith, Jessica A. Cintolo, Daniel J. Powell, Jr, Brian J. Czerniecki

Cancer Immunol Res (2015) 3 (5): 455–463.

https://doi.org/10.1158/2326-6066.CIR-14-0208

Published: 03 May 2015

View articletitled, CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/neu–Expressing Cancers

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Antitumor CD4⁺ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4⁺ Th1 Responses and Potential Use as a Cancer Vaccine

Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity

CD4⁺ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8⁺ T-cell Targeting of HER2/neu–Expressing Cancers

Email alerts

AACR Journals

Update search

Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine

Targeted Therapy Given after Anti–PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity

CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/neu–Expressing Cancers

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Antitumor CD4⁺ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells

Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4⁺ Th1 Responses and Potential Use as a Cancer Vaccine

CD4⁺ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8⁺ T-cell Targeting of HER2/neu–Expressing Cancers